CureVac N.V (CVAC) News

CureVac N.V (CVAC): $2.91

0.05 (-1.69%)

POWR Rating

Component Grades








Add CVAC to Watchlist
Sign Up

Industry: Biotech




#182 of 360

in industry

Filter CVAC News Items

CVAC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CVAC News Highlights

  • CVAC's 30 day story count now stands at 6.
  • Over the past 10 days, the trend for CVAC's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • The most mentioned tickers in articles about CVAC are SE, BNTX and EP.

Latest CVAC News From Around the Web

Below are the latest news stories about CUREVAC NV that investors may wish to consider to help them evaluate CVAC as an investment opportunity.

These Analysts Just Made A Huge Downgrade To Their CureVac N.V. (NASDAQ:CVAC) EPS Forecasts

One thing we could say about the analysts on CureVac N.V. ( NASDAQ:CVAC ) - they aren't optimistic, having just made a...

Yahoo | December 22, 2023

Rebel's Edge - December 19: $RUN, $AFRM, $CVAC, and College Football Recruits

Jon and Pete Najarian join forces to discuss and debate their favorite topics, including the hottest stock-specific news and sports!

Yahoo | December 19, 2023

Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?

A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of CureVac's intellectual property rights utilized in Comirnaty, BioNTech, and Pfizer Inc's (NYSE: PFE) mRNA COVID-19 vaccine. The ruling represents the first decision on validity in ongoing patent litigation between CureVac and BioNTech in Germany, involving eight CureVac intellectual property rights. Proc

Yahoo | December 19, 2023

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Validity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by BioNTech SE Decision does not affect ongoing litigation in Germany regarding seven other intellectual property rights, covering strong foundational ...

Yahoo | December 19, 2023

UPDATE 2-German court quashes CureVac patent after challenge by BioNTech

A German court on Tuesday invalidated a patent that was the basis of a patent violation lawsuit brought by CureVac against its domestic rival BioNTech, in a blow to CureVac's claims for a share in billions of euros in COVID-19 vaccine revenues. CureVac's Nasdaq-listed shares plunged 35% to a record low after the verdict.

Yahoo | December 19, 2023

Are Investors Undervaluing CureVac N.V. (NASDAQ:CVAC) By 26%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, CureVac fair value estimate is US$7.08 CureVac's US$5.23 share...

Yahoo | December 12, 2023

Can CureVac N.V. (CVAC) Climb 191.74% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 191.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 21, 2023

CureVac N.V. (NASDAQ:CVAC) Q3 2023 Earnings Call Transcript

CureVac N.V. (NASDAQ:CVAC) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Greetings and welcome to the CureVac Financial Results for Third Quarter and First Nine Months of 2023 Business Update. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, […]

Yahoo | November 15, 2023

CureVac N.V. (NASDAQ:CVAC) stock most popular amongst private equity firms who own 37%, while individual investors hold 31%

Key Insights The considerable ownership by private equity firms in CureVac indicates that they collectively have a...

Yahoo | November 15, 2023

Q3 2023 CureVac NV Earnings Call

Q3 2023 CureVac NV Earnings Call

Yahoo | November 15, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!